Pardes Biosciences Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a novel direct-acting, oral antiviral drug candidate designed to treat SARS-CoV-2 infections, announced the completion of its business combination with FS Development Corp. II, a special purpose acquisition company (SPAC) sponsored by Foresite Capital.
The Lancet published CanSino Biologics Inc.’s Phase III clinical trial results on the safety and efficacy of the company’s recombinant novel coronavirus vaccine, Convidecia.
J&J’s Janssen Pharmaceutical ended a collaboration with San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
The U.S. Food and Drug Administration greenlit Merck’s and Ridgeback Biotherapeutics’ molnupiravir under Emergency Use Authorization for the treatment of mild to moderate Covid-19 infections in adults who are at high risk of progression to severe disease.
According to data from real-world studies from Scotland and England, the Omicron variant does not lead to as much hospitalization as Delta.
A three-dose course of AstraZeneca’s Covid-19 vaccine is effective against the rapidly spreading Omicron coronavirus variant, the pharmaceutical company said on December 23, citing data from an Oxford University lab study.
The U.S. Food and Drug Administration approved Novartis’ Leqvio (inclisiran), the first small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.
The United States on December 22 authorized Pfizer Inc.’s antiviral Covid-19 pill for people ages 12 and older at risk of severe illness, the first oral and at-home treatment as well as a new tool against the fast-spreading Omicron variant.
Researchers globally produce hundreds of thousands of studies annually. It can be difficult to know if at some time in the future they will be the foundation for a disease cure or a technology such as CRISPR that revolutionizes medicine. But many are exciting for what they point to or how they spike the imagination. BioSpace reviews 10 of the more compelling research stories of 2021.
Novavax Inc.’s Covid-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on December 22, suggesting that the U.S. drugmaker’s existing Covid-19 vaccine can help combat the new Omicron variant.
